Company profile for Yumanity Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Yumanity Therapeutics was founded in December 2014 to serve the millions of people affected by neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. Since then, we have assembled a highly skilled team of scientists and innovators deeply committed to identifying and developing new, disease-modifying therapies that address th...
Yumanity Therapeutics was founded in December 2014 to serve the millions of people affected by neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. Since then, we have assembled a highly skilled team of scientists and innovators deeply committed to identifying and developing new, disease-modifying therapies that address these conditions. Each of our lives have been affected by the ravages of neurodegenerative diseases and it is these personal experiences that inspire our commitment to finding therapies for such devastating diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
790 Memorial Drive, Suite 2C Cambridge, MA 02139
Telephone
Telephone
617-409-5300
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com//news-release/2022/12/05/2567286/0/en/Yumanity-Therapeutics-Declares-Special-Dividend-In-Connection-with-Proposed-Asset-Sale-to-Janssen-and-Merger-with-Kineta.html

GLOBENEWSWIRE
05 Dec 2022

https://www.globenewswire.com/news-release/2022/11/14/2555009/0/en/Yumanity-Therapeutics-Reports-Third-Quarter-2022-Financial-Results-and-Recent-Corporate-Developments.html

GLOBENEWSWIRE
14 Nov 2022

https://www.globenewswire.com/news-release/2022/11/10/2553838/0/en/Yumanity-Therapeutics-Announces-Effectiveness-of-Registration-Statement-on-Form-S-4-In-Connection-With-Proposed-Asset-Sale-to-Janssen-and-Merger-with-Kineta-Inc.html

GLOBENEWSWIRE
10 Nov 2022

https://www.globenewswire.com/news-release/2022/08/29/2505759/0/en/Yumanity-Therapeutics-Announces-Filing-of-Registration-Statement-on-Form-S-4-In-Connection-With-Proposed-Asset-Sale-to-Janssen-and-Merger-with-Kineta.html

GLOBENEWSWIRE
29 Aug 2022

https://www.globenewswire.com/news-release/2022/08/04/2492847/0/en/Yumanity-Therapeutics-Reports-Second-Quarter-2022-Financial-Results-and-Recent-Corporate-Developments.html

GLOBENEWSWIRE
04 Aug 2022

https://www.globenewswire.com/news-release/2022/06/06/2456507/0/en/Yumanity-Therapeutics-Announces-Definitive-Agreements-for-Two-Strategic-Transactions.html

GLOBENEWSWIRE
06 Jun 2022

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty